Novogen is a rapidly expanding international biotechnology company based in Australia and the USA.


Novogen has three key aims:



  1. To maintain its position as the world leader in the area of isoflavonoid drug technology;

  2. To convert the Novogen technology platform into products that will successfully treat and prevent the major degenerative diseases of humans;

  3. To establish a business model and investment opportunity that will return increasing value to shareholders.


 








Novogen regains compliance with Nasdaq Listing Rules
23 January 2012

Novogen Limited (ASX: NRT NASDAQ:NVGN) - In addition to the ...More



Marshall Edwards issued with new method of use patent for ME-344
3 January 2012

Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: ...More



Novogen modifies its ADR program and makes further investment into Marshall Edwards
30 December 2011

Sydney Australia – 30 December, 2011 – The Company today ...More






Chairman's address at Novogen EGM
Friday, 6 May 2011

Novogen Extraordinary Meeting

Chairman’s Address

6 May, 2011

Welcome to the Novogen Extraordinary
...More
 


About Novogen | Knowledge Base | Pharmaceuticals | News | Investor Relations | Contact | Site Map
Copyright © 2012 Novogen The world leader in isoflavone research - with products including Promensil and Trinovin | Web Design by Newgency